reported that that the among melanoma patients, overexpression of PSMB8 and PSMB9 was predictive for better survival and improved response to immune-checkpoint inhibitors (26), and these genes were highly expressed in the low-risk group (Figures 8E, F). The gene discussed is PSMB9; the disease is melanoma.